Announced Fri, 7 Aug · 11:42 IST
Transgene Biotek Q1 FY27 results: loss narrows to Rs 38.9 lakh, revenue up 21%
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.7%1-day move
₹2.86
prior close
₹2.98
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.3+0.3+0.3+0.3+1.7+2.4+3.8+4.2-4.2-0.3+1.4-5.9——
Up moveDown movePending
AI summary
Transgene Biotek posted Q1 FY27 revenue of Rs 6.00 lakh, up 21% from Rs 4.95 lakh YoY. Net loss narrowed to Rs 38.90 lakh from Rs 43.37 lakh. EPS stood at minus 0.05. Board also appointed M/s Manisha Dubey & Associates as internal auditors for FY 2026-27 and extended AGM date. Company has ongoing legal matters at NCLT, SAT, and ED tribunal.
Likely market impact
Loss continues but is narrowing. Revenue grew modestly. Multiple legal matters pending. Caution advised for investors.